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OBJECTIVES: The Israeli National Health Insurance Law stipulates a National 
List of Health Services that all residents are entitled to. In March 2008, two tyrosine 
kinase inhibitors (TKIs), sorafenib and sunitinib, were added to the formulary indi-
cated and limited for ﬁrst-line treatment of metastatic renal cell carcinoma (mRCC). 
Oncologists could prescribe only one TKI, and patients are not eligible to subsequently 
receive the other. After 15 months on the formulary, we compared oncologists’ pre-
scribing preferences, treatment duration (TD), and survival in patients with mRCC 
treated with sorafenib or sunitinib. METHODS: We used demographic and claims 
data from Clalit Health Services’ 3.5 million client computerized database to identify 
all mRCC patients treated with either sorafenib or sunitinib since March 2008. Mean 
and median TD and patient survival were calculated and compared using a Kaplan-
Meir analysis. RESULTS: Through the end of May 2009, 134 patients received 
sunitinib as initial therapy for mRCC, 29 patients received sorafenib. The two groups 
had similar demographic characteristics: mean (SD) age was 66.2 (o12.8) for sunitinib 
patients and 69.4 (o10.7) for sorafenib patients (p  0.212). Approximately 63% 
of the subjects in each group were males. Mean TDs were 8.0 months (95% CI 6.8–
9.0) and 5.7 months (95% CI 3.8–7.8) for sunitinib and sorafenib, respectively (p  
0.071). Median TDs were 7.0 months (95% CI 4.4–9.6) and 3.0 months (95% CI 
1.4–4.6) for sunitinib and sorafenib, respectively. Mean survival times were 11.3 
months (95% CI 10.4–12.2) and 8.1 months (95% CI 6.1–10.1) for sunitinib and 
sorafenib patients, respectively (p  0.023). CONCLUSIONS: Our retrospective analy-
sis suggests that Israeli oncologists strongly prefer prescribing sunitinib for ﬁrst line 
treatment of mRCC. Mean and median TDs and survival were longer for patients 
treated with sunitinib. Future analyses must control for patient clinical characteristics, 
which may have been a major factor in treatment preferences, and might have inﬂu-
enced TD and survival.
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OBJECTIVES: For pts with N BC, CT with a taxane is a standard treatment, 
followed by endocrine therapy as indicated. Letrozole (LET) has shown an overall 
survival (OS) beneﬁt relative to tamoxifen (TAM) in postmenopausal women with 
N BC. To assess the relative survival beneﬁts of these interventions, we calculated 
the NNT to prevent one death. METHODS: Five-year survival data was taken 
from a pivotal randomized controlled trial (RCT) for LET (N pts from BIG 1-98, 
TAM arm censored for crossover to LET) and from three RCTs of adjuvant taxane 
CT regimens (AC-T, FEC-D, and DAC). These studies were selected based on 
comparable follow up and exclusion/inclusion criteria. NNT was calculated with 
respect to OS at 5 yrs; outcome is presented as the NNT to save a life. RESULTS: 
The NNT for OS for adjuvant LET vs. TAM was 27 based on BIG 1-98 in N BC 
pts; this was comparable to the NNTs for taxane based therapies as shown below. 
CONCLUSIONS: The magnitude of OS beneﬁt seen with LET over TAM in BIG 1-98 
is similar to that seen with adjuvant taxane based CT regimens. Taxanes are part 
of standard management of adjuvant BC. These data support the standard use 
of LET/AIs as well. The studies BIG 1-981: LET vs. TAM, 27; PACS012: FEC-D vs. 
FEC, 25; BCIRG 001 3: DAC vs. FAC, 17; CALGB 9344 4: ACàT vs. AC, 34 for 
Exp vs. Controls, OS NNT. F  Fluorouracil E  Epirubicin C  Cyclophosphamide 
D  Docetaxel T  Paclitaxel A  Doxorubicin. 1Mouridsen 08 2Roche 06 3Martin 05 
4Henderson 03.
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OBJECTIVES: Large multinational clinical trials, namely ATAC and BIG 1-98, dem-
onstrated that anastrozole (ANA) and letrozole (LET) were superior to tamoxifen 
(TAM) in preventing disease recurrence in postmenopausal women with early breast 
cancer. The number needed to treat approach (NNT) is an effective method to express 
multiple ﬁndings from randomized trials in a clinically meaningful way. LET and ANA 
had comparable NNT for all recurrences at 2 and 2.5 years, respectively; however, 
NNT for distant recurrence was 3-fold fewer with LET vs. ANA. Long term follow-up 
(FU) of BIG 1-98 and ATAC trials suggested potential differences between LET and 
ANA in overall survival (OS). In this exploratory analysis, the NNT approach was 
used to compare LET and ANA in avoiding death. METHODS: An essential require-
ment for NNT analyses is to consider outcomes over similar FU periods. The OS data 
for ANA from ATAC (median FU: 68 months; HR  0.97) and for LET from BIG 1-
98, (median FU: 76 months; HR  0.81) were used in this analysis. In the BIG 1-98 
trial the censored analysis was included as it remained unblinded (similar to ATAC 
trial). In the ATAC trial only data for HRve subanalysis was included. Nearly all pts 
in BIG 1-98 (99%) were HR. RESULTS: Fewer pts needed to be treated with LET 
than ANA to avoid one death compared to TAM, 63 (95% CI: 39–500) and 161 
(95% CI: 38–c) pts respectively; representing a 2.5-fold difference. CONCLUSIONS: 
The lower NNT associated with LET in BIG 1-98 to avoid one death compared to 
ANA in ATAC could be due to the signiﬁcant reduction in early distant recurrence 
observed with LET, which may translate into a survival beneﬁt.
PCN23
PHARMACOEPIDEMIOLOGY OF PATIENTS TREATED  
WITH TEMOZOLOMIDE
Brignone M1, Borget I2, Hassani Y3, Bertholle V4, Billard M4, Lefebre MN5, Schlemmer C5, 
Charlety D6, Audeval C7, Raingeard E7, Daouphars M8, Pinguet F9, Fabbro M9,  
Chevrier R10, Tilleul P11
1St-Antoine Hospital, Paris, France, 2Institut de Cancérologie Gustave Roussy, Villejuif, France, 
3Saint-Antoine Hospital, Pharmacy, Paris, France, 4CHU Lyon, Lyon, France, 5CHRU de Lille, 
Lille, France, 6CHU Grenoble, Grenoble, France, 7Institut Gauducheau, Saint-Herblain, France, 
8Pharmacy CLNCC, Rouen, Rouen, France, 9Pharmacy CRLCC, Montpellier, France, 
Montpellier, France, 10Jean Perrin, Clermont-Ferrand, France, 11St-Antoine Hospital and 
Pharmacy University Paris-Descartes, Paris, Paris, France
OBJECTIVES: Temozolomide (TMZ) is an oral alkylating cytotoxic agent prescribed         
in monotherapy or in association with radiotherapy. TMZ is indicated in the treatment 
of high-grade brain tumours (glioblastoma multiforme and astrocytomas). However, 
TMZ is also used off-label. The main objective of this observational study was to 
assess the conformity of the use of TMZ in clinical practices. The secondary objective 
was to identify all indications in which TMZ was prescribed. METHODS: A French  
prospective multicenter study related to consecutive patients treated by TMZ was 
performed in 21 hospitals. Patients’ characteristics and drug prescriptions parameters, 
in terms of indications, dosages, treatment length, association with other drugs, side 
effects and prophylactic drugs, were collected. The level of conformity was analyzed 
in comparison with the market authorization and a prescription guideline elaborated 
by clinical experts and pharmacists. RESULTS: A total of 831 patients (median age    
56 y; men: 57%) representing a total of 5982 TMZ cures were registered. TMZ was 
mainly prescribed in glioblastoma multiforme newly diagnosed or in relapse (51%), 
in anaplastic oligodendrogliomas (27%) and in anaplastic oligoastrocytomas (10%). 
TMZ was prescribed in malignant melanomas in 3% of cases. During monotherapy, 
the mean daily dose was 173 mg o 35 mg/m2. Ninety percent of patients received the 
planned duration of cycle. Thirty-three percent of side effects were observed. More 
than half of patients were co-treated by antiemetics (86%) and antiepileptics (63%). 
Indications were conformed to the guideline in 91% of cases but only in 54% in 
accordance with the market authorization. As compared to the market authorization, 
conformity rate was respectively observed in 76%, 84%, 90% 88% and 78% in terms 
of dosages, TMZ duration, cycle duration, associations, total length of treatment, 
leading to a global conformity of 54%. CONCLUSIONS: In this study, TMZ prescrip-    
tion appears highly conform to the guideline but lower when compared to the market 
authorization.
PCN24
CLINICAL OUTCOMES AND HEALTH CARE RESOURCE UTILISATION 
OF PATIENTS RECEIVING LAPATINIB FOR BREAST CANCER IN 
FRANCE: THE LAPS STUDY (LAPATINIB ATU PARCOURS DE SOINS)
Perrocheau G1, Tehard B2, Terpereau A2, Campone M3
1Centre Renée Gauducheau, Saint Herblain, France, 2GlaxoSmithKline, Marly-le-Roi, France, 
3Centre René Gauducheau, Saint Herblain, France
BACKGROUND: lapatinib (Tyverb Ò) is an oral small molecule inhibitor of ErbB1 
and ErbB2. Lapatinib in combination with capecitabine has been approved for the 
treatment of patients with HER2 advanced or metastatic breast cancer (MBC). 
Since January 2007 prior to its European registration, lapatinib was made available 
to patients through the (ATU). The full oral course of lapatinib  capecitabine 
does not require any hospital infusion. This may have a positive impact on care con-
sumption. OBJECTIVES: To describe clinical outcomes and health care resource 
utilisation of patients receiving lapatinib in the scope of the ATU, an everyday 
practice setting. METHODS: Observational, retrospective study in patients who 
entered the ATU between January 1, 2007 and September 30, 2007. Data were col-
lected from patients’ medical ﬁles between February 21, 2008 and April 30, 2008. 
RESULTS: A total of 198 patients were included (mean age       55yrs). Most patients 
had already received 4 prior metastatic regimens. At this time, patients presented liver 
(53%), bone (52%) and brain (40%) metastases. 49% of patients responded positively 
to the treatment. The study showed a median TTP of 23 weeks. A median OS of 41.6 
weeks was estimated with Kaplan-Meier survival analysis. While receiving lapatinib, 
53% of patients had no hospitalization and 19% had only day admissions. In 70% 
hospitalizations were associated with disease progression while day admissions were 
associated with treatment follow-up (74%). Only 11% of hospitalizations and 2% of 
day admissions were associated with toxicity. Sixty-eight of patients had a consulta-
tion (inside or outside hospital). CONCLUSIONS: this study provides the ﬁrst data 
on health care resource utilisation with lapatinib use in the French current medical 
practice. Clinical outcomes are consistent with trial results for advanced treatment 
lines. The study shows a limited care consumption driven by a very low rate of 
hospitalization.
